The use of animal models in multiple myeloma

Morphologie

Volumn 99, Issue 325, 2015, Pages 63-72

  Libouban, H ^a  

^a UNIV Angers   (France)

Author keywords

5T2MM; 5T33MM; 5TGM1; BALB c; C57BL KalwRij; Murine model of myeloma; Osteolysis; Pristane; SCID; SCID hu; Xenograft

Indexed keywords

BONE MARROW CELL; CANCER THERAPY; CELL GROWTH; CELL ISOLATION; CELL PROLIFERATION; HUMAN; IN VITRO STUDY; MOUSE MODEL; MULTIPLE MYELOMA; NOD SCID MOUSE; NONHUMAN; OSTEOLYSIS; PLASMA CELL; PLASMACYTOMA; REVIEW; SCID MOUSE; ANIMAL; ANIMAL MODEL; BAGG ALBINO MOUSE; BONE TRANSPLANTATION; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CLONE; CHEMICALLY INDUCED; DRUG EFFECTS; FETAL TISSUE TRANSPLANTATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONOBESE DIABETIC MOUSE; OSTEOBLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT; TRANSPLANTATION; TUMOR MICROENVIRONMENT; XENOGRAFT;

ANTINEOPLASTIC AGENT; PRISTANE; TERPENE; TUMOR PROTEIN;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE TRANSPLANTATION; CLONE CELLS; FETAL TISSUE TRANSPLANTATION; HETEROGRAFTS; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MODELS, ANIMAL; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; OSTEOBLASTS; PLASMA CELLS; PLASMACYTOMA; RABBITS; TERPENES; TUMOR MICROENVIRONMENT;

EID: 84942980995     PISSN: 12860115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.morpho.2015.01.003     Document Type: Review

References (82)

1. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435-41.
2. Edwards CM, Zhuang J, Mundy GR. The pathogenesis of thebone disease of multiple myeloma. Bone 2008;42:1007-13.
3. Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR, et al. Cell-cell contact between mar-row stromal cells and myeloma cells via VCAM-1 andalpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000;96:1953-60.
4. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprote-gerin/osteoprotegerin ligand system in the human bonemarrow environment. Blood 2001;98:3527-33.
5. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bonemarrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712-20.
6. Feliers D, WoodruffK, Abboud S. Potential role of insulin-like growth factor binding protein-4 in the uncouplingof bone turnover in multiple myeloma. Br J Haematol 1999;104:715-22.
7. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005;106:3160-5.
8. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the develop-ment of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94.
9. Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, et al. IL-3 is a potential inhibitor of osteoblast differentiationin multiple myeloma. Blood 2005;106:1407-14.
10. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, et al. Myeloma cells block RUNX2/CBFA1 activity in human bonemarrow osteoblast progenitors and inhibit osteoblast formationand differentiation. Blood 2005;106:2472-83.
11. Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, et al. HGF inhibits BMP-induced osteoblastogen-esis: possible implications for the bone disease of multiplemyeloma. Blood 2007;109:3024-30.
12. Gado K, Silva S, Paloczi K, Domjan G, Falus A. Mouse plasma-cytoma: an experimental model of human multiple myeloma. Haematologica 2001;86:227-36.
13. Potter M. Experimental plasmacytomagenesis in mice. Hematol Oncol Clin North Am 1997;11:323-47.
14. LeGrand J, Park ES, Wang H, Gupta S, Owens Jr JD, Nel-son PJ, et al. Global gene expression profiling in mouseplasma cell tumor precursor and bystander cells reveals poten-tial intervention targets for plasma cell neoplasia. Blood 2012;119:1018-28.
15. Park ES, Shaughnessy Jr JD, Gupta S, Wang H, Lee JS, Woo HG, et al. Gene expression profiling reveals different path-ways related to Abl and other genes that cooperate with c-Mycin a model of plasma cell neoplasia. BMC Genomics 2007;8:302.
16. Potter M, Wiener F. Plasmacytomagenesis in mice: model ofneoplastic development dependent upon chromosomal translo-cations. Carcinogenesis 1992;13:1681-97.
17. Silva S, Kovalchuk AL, Kim JS, Klein G, Janz S. BCL2 acceleratesinflammation-induced BALB/c plasmacytomas and promotesnovel tumors with coexisting T(12;15) and T(6;15) transloca-tions. Cancer Res 2003;63:8656-63.
18. Barille S, Bataille R, Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex inthe pathogenesis of multiple myeloma. Eur Cytokine Netw 2000;11:546-51.
19. Hilbert DM, Kopf M, Mock BA, Kohler G, RudikoffS. Interleukin6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995;182:243-8.
20. Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P, et al. Defective development of pristane-oil-inducedplasmacytomas in interleukin-6-deficient BALB/c mice. Am JPathol 1997;151:689-96.
21. Henk HJ, Teitelbaum A, Perez JR, Kaura S. Persistency withzoledronic acid is associated with clinical benefit in patientswith multiple myeloma. Am J Hematol 2012;87:490-5.
22. Avcu F, Ural AU, Yilmaz MI, Ozcan A, Ide T, Kurt B, et al. The bisphosphonate zoledronic acid inhibits the developmentof plasmacytoma induced in BALB/c mice by intraperitonealinjection of pristane. Eur J Haematol 2005;74:496-500.
23. Alsina M, Boyce B, Devlin RD, Anderson JL, Craig F, Mundy GR, et al. Development of an in vivo model of human multiplemyeloma bone disease. Blood 1996;87:1495-501.
24. Hjorth-Hansen H, Seifert MF, Borset M, Aarset H, Ostlie A, Sundan A, et al. Marked osteoblastopenia and reduced boneformation in a model of multiple myeloma bone disease insevere combined immunodeficiency mice. J Bone Miner Res 1999;14:256-63.
25. Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, et al. Fluorescence imaging of multiple myeloma cellsin a clinically relevant SCID/NOD in vivo model: biologic andclinical implications. Cancer Res 2003;63:6689-96.
26. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients withaggressive or minimal disease: engraftment and self-renewalof primary human myeloma in the bone marrow of NOD SCIDmice. Blood 2000;95:1056-65.
27. Tsunenari T, Koishihara Y, Nakamura A, Moriya M, Ohkawa H, Goto H, et al. New xenograft model of multiple myeloma andefficacy of a humanized antibody against human interleukin-6receptor. Blood 1997;90:2437-44.
28. Goto H, Shimazaki C, Tatsumi T, Yamagata N, Fujita N, Tsuchiya M, et al. Establishment of a novel myeloma cell line KPMM2carrying t(3;14)(q21;q32), which proliferates specifically inresponse to interleukin-6 through an autocrine mechanism. Leukemia 1995;9:711-8.
29. Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bonedisease. J Clin Invest 2001;108:1833-41.
30. Cruz JC, Alsina M, Craig F, Yoneda T, Anderson JL, Dallas M, et al. Ibandronate decreases bone disease development andosteoclast stimulatory activity in an in vivo model of humanmyeloma. Exp Hematol 2001;29:441-7.
31. Sordillo EM, Pearse RN. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 2003;97:802-12.
32. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The5TMM series: a useful in vivo mouse model of human multiplemyeloma. Hematol J 2000;1:351-6.
33. Ahsmann EJ, van Tol MJ, Oudeman-Gruber J, Lokhorst H, Uyt-dehaag FG, Schuurman HJ, et al. The SCID mouse as a modelfor multiple myeloma. Br J Haematol 1995;89:319-27.
34. Feo-Zuppardi FJ, Taylor CW, Iwato K, Lopez MH, Grogan TM, Odeleye A, et al. Long-term engraftment of fresh humanmyeloma cells in SCID mice. Blood 1992;80:2843-50.
35. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cellsgrowing in SCID-hu mice: a model for studying the biol-ogy and treatment of myeloma and its manifestations. Blood 1998;92:2908-13.
36. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, et al. Anti-DKK1 mAb (BHQ880) as apotential therapeutic agent for multiple myeloma. Blood 2009;114:371-9.
37. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerincytokine axis to trigger bone destruction and promote tumorprogression. PNAS 2001;98:11581-6.
38. Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-humodel. Blood 2002;100:4162-8.
39. Yata K, Yaccoby S. The SCID-rab model: a novel in vivo systemfor primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004;18:1891-7.
40. Radl J, Hollander CF, van den Berg P, de Glopper E. Idiopathicparaproteinaemia. I. Studies in an animal model-the ageingC57BL/KaLwRij mouse. Clin Exp Immunol 1978;33:395-402.
41. Radl J. Multiple myeloma and related disorders. Lessons froman animal model. Pathol Biol (Paris) 1999;47:109-14.
42. Libouban H, Onno C, Pascaretti-Grizon F, Gallois Y, Moreau MF, Baslé MF, et al. Absence of renal lesions in C57BL/KaLwRijmice with advanced myeloma due to 5T2MM cells. Leuk Res 2006;30:1371-5.
43. Vanderkerken K, De Raeve H, Goes E, Van Meirvenne S, Radl J, Van Riet I, et al. Organ involvement and phenotypic adhesionprofile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRijmouse. Br J Cancer 1997;76:451-60.
44. Garrett IR, Dallas S, Radl J, Mundy GR. A murine model ofhuman myeloma bone disease. Bone 1997;20:515-20.
45. Alici E, Konstantinidis KV, Aints A, Dilber MS, Abedi-Valugerdi M. Visualization of 5T33 myeloma cells in the C57BL/KaLwRijmouse: establishment of a new syngeneic murine model ofmultiple myeloma. Exp Hematol 2004;32:1064-72.
46. Oyajobi BO, Munoz S, Kakonen R, Williams PJ, Gupta A, Wide-man CL, et al. Detection of myeloma in skeleton of miceby whole-body optical fluorescence imaging. Mol Cancer Ther 2007;6:1701-8.
47. Asosingh K, Gunthert U, Bakkus MH, De Raeve H, Goes E, VanRiet I, et al. In vivo induction of insulin-like growth factor-Ireceptor and CD44v6 confers homing and adhesion to murinemultiple myeloma cells. Cancer Res 2000;60:3096-104.
48. Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K. Myeloma cells (5TMM) and their interac-tions with the marrow microenvironment. Blood Cells Mol Dis 2004;33:111-9.
49. Libouban H, Moreau MF, Lesourd M, Baslé MF, Chappard D. Osteolytic bone lesions in the 5T2 multiple myeloma model:radiographic, scanning electron microscopy and microtomo-graphic studies. J Histotechnol 2001;24:81-6.
50. Vanderkerken K, Goes E, De Raeve H, Radl J, Van Camp B. Follow-up of bone lesions in an experimental multiplemyeloma mouse model: description of an in vivo techniqueusing radiography dedicated for mammography. Br J Cancer 1996;73:1463-5.
51. Libouban H, Moreau MF, Basle MF, Bataille R, Chappard D. Selec-tion of a highly aggressive myeloma cell line by an alteredbone microenvironment in the C57BL/KaLwRij mouse. BiochemBiophys Res Commun 2004;316:859-66.
52. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE. Evi-dence of the secretion of an osteoclast stimulating factor inmyeloma. N Engl J Med 1974;291:1041-6.
53. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, et al. Osteoprotegerin inhibits the development of osteolyticbone disease in multiple myeloma. Blood 2001;98:3534-40.
54. Buckle CH, De Leenheer E, Lawson MA, Yong K, Rabin N, Perry M, et al. Soluble rank ligand produced by myeloma cellscauses generalised bone loss in multiple myeloma. PLoS One 2012;7:e 41127.
55. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor kappa B ligand-osteoprotegerin ratio predicts survival in mul-tiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064-9.
56. Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S, et al. Dual effects of macrophage inflam-matory protein-1alpha on osteolysis and tumor burden inthe murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311-9.
57. Noll JE, Williams SA, Tong CM, Wang H, Quach JM, Purton LE, et al. Myeloma plasma cells alter the bone marrow microen-vironment by stimulating the proliferation of mesenchymalstromal cells. Haematologica 2014;99:163-71.
58. Libouban H, Moreau MF, Baslé MF, Bataille R, Chappard D. Increased bone remodeling due to ovariectomy dramaticallyincreases tumoral growth in the 5T2 multiple myeloma mousemodel. Bone 2003;33:283-92.
59. Libouban H, Le Drevo MA, Moreau MF, Baslé MF, Chappard D. Dietary calcium deficiency increases osteolysis and mod-ifies gene expression profile in an animal model of multiplemyeloma. Calcif Tissue Int 2008;82:S35.
60. Benameur T, Chappard D, Fioleau E, Andriantsitohaina R, Mar-tinez MC, Clere N, et al. Plasma cells release membranemicroparticles in a mouse model of multiple myeloma. Micron 2013;54-55:75-81.
61. Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB, et al. SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia 2014;16:572-85.
62. Manning LS, Chamberlain NL, Leahy MF, Cordingley FT. Assess-ment of the therapeutic potential of cytokines, cytotoxic drugsand effector cell populations for the treatment of multiplemyeloma using the 5T33 murine myeloma model. Immunol Cell Biol 1995;73:326-32.
63. Croese JW, Vissinga CS, Boersma WJ, Radl J. Immune regulationof mouse 5T2 multiple myeloma. I. Immune response to 5T2 MMidiotype. Neoplasma 1991;38:457-66.
64. Radl J, Croese JW, Zurcher C, van den Enden-Vieveen MH, Brondijk RJ, Kazil M, et al. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiplemyeloma. Cancer 1985;55:1030-40.
65. Dallas SL, Garrett IR, Oyajobi BO, Dallas MR, Boyce BF, Bauss F, et al. Ibandronate reduces osteolytic lesions but not tumorburden in a murine model of myeloma bone disease. Blood 1999;93:1697-706.
66. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lip-pitt J, et al. Zoledronic acid treatment of 5T2MM-bearing miceinhibits the development of myeloma bone disease: evidencefor decreased osteolysis, tumor burden and angiogenesis, andincreased survival. J Bone Miner Res 2003;18:482-92.
67. Edwards CM, Mueller G, Roelofs AJ, Chantry A, Perry M, Rus-sell RG, et al. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is asso-ciated with a modulation of myeloma in vivo. Int J Cancer 2007;120:1657-63.
68. Derenne S, Amiot M, Barillé S, Collette M, Robillard N, Berthaud P, et al. Zoledronate is a potent inhibitor of myeloma cellgrowth and secretion of IL-6 and MMP-1 by the tumoral envi-ronment. J Bone Miner Res 1999;14:2048-56.
69. N'Diaye M, Libouban H, Aguado E, Bouvard B, Audran M, Chappard D. Unwrapping microcomputed tomographicimages for measuring cortical osteolytic lesions in the 5T2murine model of myeloma treated by bisphosphonate. Micron 2015;68:98-106.
70. Webb SL, Edwards CM. Novel therapeutic targets in myelomabone disease. Br J Pharmacol 2014;171:3765-76.
71. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, et al. Selective inhibitors of the osteoblast proteasomestimulate bone formation in vivo and in vitro. J Clin Invest 2003;111:1771-82.
72. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, et al. Bortezomib alone or in combination with the his-tone deacetylase inhibitor JNJ-26481585: effect on myelomabone disease in the 5T2MM murine model of myeloma. Cancer Res 2009;69:5307-11.
73. Zangari M, Berno T, Yang Y, Zeng M, Xu H, Pappas L, et al. Parathyroid hormone receptor mediates the anti-myelomaeffect of proteasome inhibitors. Bone 2014;61:39-43.
74. Cherel M, Gouard S, Gaschet J, Sai-Maurel C, Bruchertseifer F, Morgenstern A, et al. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiplemyeloma. J Nucl Med 2013;54:1597-604.
75. Gouard S, Pallardy A, Gaschet J, Faivre-Chauvet A, Bruchert-seifer F, Morgenstern A, et al. Comparative analysis of multiplemyeloma treatment by CD138 antigen targeting with bismuth-213 and melphalan chemotherapy. Nucl Med Biol 2014;41Suppl.:e30-5.
76. Sanchez E, Chen H, Berenson JR. In vivo models of multiplemyeloma (MM). Biochem Pharmacol 2014;89:313-20.
77. Harley JB, Schilling A, Glidewell O. Ineffectiveness of fluoridetherapy in multiple myeloma. N Engl J Med 1972;286:1283-8.
78. Kyle RA, Jowsey J, Kelly PJ, Taves DR. Multiple-myelomabone disease. The comparative effect of sodium fluorideand calcium carbonate or placebo. N Engl J Med 1975;293:1334-8.
79. Pennisi A, Ling W, Li X, Khan S, Wang Y, Barlogie B, et al. Consequences of daily administered parathyroid hormone onmyeloma growth, bone disease, and molecular profiling ofwhole myelomatous bone. PLoS One 2010:5.
80. Kang MG, Won EJ, Choi HW, Kim HR, Choi HJ, Park HR, et al. Serum parathyroid hormone is a new potential risk factor inmultiple myeloma. Biomed Res Int 2014;2014:804182-282.
81. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, et al. Increasing Wnt signaling in the bone mar-row microenvironment inhibits the development of myelomabone disease and reduces tumor burden in bone in vivo. Blood 2008;111:2833-42.
82. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy Jr JD, Evans HR, et al. Inhibiting Dickkopf-1 (Dkk1) removes sup-pression of bone formation and prevents the development ofosteolytic bone disease in multiple myeloma. J Bone Miner Res 2009;24:425-36.